Milestone Pharmaceuticals
MIST
25 hedge funds and large institutions have $350M invested in Milestone Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53.41% more ownership
Funds ownership: 0% → 53.41% (+53%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$72.6M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$55.1M |
| 3 |
VMI
VHCP Management III
New York
|
+$42.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.8M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$22.7M |
Top Sellers
MIST Hedge Fund Activity: Q2 2019 in Review
25 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2019, worth a combined $350M.
Buyers outnumbered sellers: 25 funds opened new MIST positions and 0 closed out — a net gain of 25 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $72.6M.
- 25 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $350M of Milestone Pharmaceuticals stock for Q2 2019.
- 25 funds opened new Milestone Pharmaceuticals positions in Q2 2019 and 0 closed out, a net change of +25 holders.
- The largest Milestone Pharmaceuticals buyer in Q2 2019 was RTW Investments, an estimated $72.6M added.
Based on aggregated 13F filings for Q2 2019.